An investigational in vivo gene insertion therapy for neonatal onset Ornithine Transcarbamylase (OTC) deficiency using ARCUS® nuclease and AAV vectors to insert a healthy OTC gene into liver cells.

A mutation-agnostic gene editing platform that inserts full healthy copies of disease-causing genes into patient chromosomes using ARCUS® nuclease and AAV vectors, primarily targeting liver disorders.